Selarsdi

NDC 51759-708 · Teva Pharmaceuticals USA, Inc.

Generic nameustekinumab-aekn

Dosage formINJECTION, SOLUTION

RouteINTRAVENOUS

Active ingredient(s)USTEKINUMAB-AEKN

Strength130 mg/26mL

Pharmacologic classInterleukin-12 Antagonist [EPC], Interleukin-12 Antagonists [MoA], Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]

Marketing categoryBLA

Packages

51759-708-13 — 1 VIAL, GLASS in 1 CARTON (51759-708-13) / 26 mL in 1 VIAL, GLASS

Billed under HCPCS

Q9998 — Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg Medicare Part B payment limit (ASP + 6%): $10.53

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

51759-413 — ustekinumab-aekn, 51759-414 — ustekinumab-aekn, 51759-505 — ustekinumab-aekn, 51759-607 — ustekinumab-aekn, 51759-709 — ustekinumab-aekn, 51759-710 — ustekinumab-aekn

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels